GlassScriptPhysician profile
Lawrence Schilder
NPI 1962439398
$7,723.99
in general payments reported to CMS, 2019-2025
62 companies · $394 in 2025
The $394 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,778 · 2020: $1,984 · 2021: $1,833 · 2022: $1,618 · 2023: $116 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $510.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $608.31 | 2019-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $517.35 | 2019-2022 | |
| Amgen INC. | $475.26 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $456.82 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $453.88 | 2019-2023 | |
| Genentech USA, INC. | $376.67 | 2019-2022 | |
| Exelixis INC. | $348.18 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $343.45 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $331.88 | 2019-2022 | |
| Incyte Corporation | $328.39 | 2019-2022 | |
| Genzyme Corporation | $293.51 | 2019-2022 | |
| Celgene Corporation | $251.77 | 2019-2022 | |
| Eisai INC. | $185.22 | 2020-2022 | |
| Astellas Pharma US INC | $170.61 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $169.88 | 2019-2021 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Schilder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.